once weekly glp 1 agonist GLP-1 Agonists—commonly used for weight loss and diabetes—are now being linked to serious eye health concerns, including an increased risk of a condition called NAION, which can cause irreversible blindness. With GLP-1 Another Weight-Loss Trial Win for
Description
Glucose-lowering treatments and COVID-19 mortality in T2DM
Duration of treatment comparison Trial duration differences complicate raw comparisons
In summary, convergent evidence from both preclinical and clinical research underscores the capacity of GLP-1RAs to interact with neural circuits that govern reinforcement and motivation, networks that are also targeted by drugs of abuse
The ADA notes that medication adjustments should be individualized based on the patient's glycemic control, with appropriate glucose monitoring during any interruption period
NAION is caused by a sudden interruption of blood flow to the optic nerve, leading to rapid, painless, and often irreversible vision loss
Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Trends and Insights The rise in Insulin Drug Pricing in Europe Insulins have been in the market for decades
